Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on August 6, 2025. The filing discloses an update on the ELIMINATE-B Phase 1 clinical trial evaluating PBGENE-HBV, a gene-editing therapy for chronic hepatitis B. The report covers safety and efficacy data for Cohort 1 and preliminary safety data for Cohort 2.
Key Financial Metrics
This filing is a non-financial disclosure regarding clinical trial progress. The document does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. Investors should refer to the Company's most recent Form 10-Q or 10-K for financial data.
Material Changes and Clinical Results
- Cohort 1 (0.2 mg/kg): Three patients received three planned doses. The treatment was well-tolerated with no Grade 2+ treatment-related adverse events, serious adverse events, or dose-limiting toxicities.
- Efficacy: All three patients showed substantial HBsAg reduction (56%, 69%, and 47% from baseline). One patient (33%) achieved a durable reduction of approximately 50% maintained seven months post-initial dose.
- Cohort 2 (0.4 mg/kg): Preliminary data shows no adverse events above Grade 2 or dose-limiting toxicities in patients who received doses. One patient experienced a transient infusion-related serious adverse event that resolved quickly; the Data Monitoring Committee (DMC) deemed it not dose-related.
Guidance, Outlook, and Risks
The Company expects to complete dosing for Cohort 2 and commence Cohort 3, with a data update anticipated later in 2025. The DMC has recommended initiating Cohort 3 based on the favorable safety profile of the first two cohorts. The filing includes standard forward-looking statement disclaimers regarding risks associated with clinical development, regulatory approval, and operational strategies.
Key Facts for Investor Verification
- Verify the durability of the HBsAg reduction in the single responder from Cohort 1 beyond the July 28, 2025 data cutoff.
- Monitor the full safety profile of Cohort 2 as more patients complete the three-dose regimen.
- Confirm the timeline for Cohort 3 initiation and subsequent data readouts.
- Review the Company's cash runway in recent financial filings, as this clinical progress does not immediately impact revenue.